Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ishimoto, O.
Right arrow Articles by Ikawa, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ishimoto, O.
Right arrow Articles by Ikawa, S.
[Cancer Research 62, 636-641, February 1, 2002]
© 2002 American Association for Cancer Research

Advances in Brief

Possible Oncogenic Potential of {Delta}Np73

A Newly Identified Isoform of Human p731

Osamu Ishimoto, Chikashi Kawahara, Kentaro Enjo, Masuo Obinata, Toshihiro Nukiwa and Shuntaro Ikawa1

Departments of Cell Biology [O. I., C. K., K. E., M. O., S. I.], Respiratory Oncology and Molecular Medicine [O. I., T. N.], Institute of Development, Aging and Cancer, Tohoku University, Sendai 980-8575, Japan

p73, a recently identified gene highly homologous to p53, can transactivate p53 target genes and induce apoptosis. Here we report the identification of an NH2-terminal truncated isoform of human p73, {Delta}Np73, which is capable of suppressing p53- and p73-dependent transactivation. We speculate that this suppression is achieved by competing for the DNA binding site in the case of p53 and by direct association in the case of TAp73. Expression of {Delta}Np73 in cancer cell lines also inhibited suppressive activity of p53 and TAp73 in colony formation, implying possible involvement of {Delta}Np73 in oncogenesis by inhibiting the tumor-suppressive function of p53 and TAp73. Also reported is the identification of TAp73{eta}, a new member of the COOH-terminal truncated isoform of p73 and tissue-specific expression of these isoforms, along with other previously identified p73 isoforms.




This article has been cited by other articles:


Home page
 GENES CELLSHome page
A. Kurihara, H. Nagoshi, M. Yabuki, R. Okuyama, M. Obinata, and S. Ikawa
Ser46 phosphorylation of p53 is not always sufficient to induce apoptosis: multiple mechanisms of regulation of p53-dependent apoptosis
Genes Cells, July 1, 2007; 12(7): 853 - 861.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Futamura, H. Kamino, Y. Miyamoto, N. Kitamura, Y. Nakamura, S. Ohnishi, Y. Masuda, and H. Arakawa
Possible Role of Semaphorin 3F, a Candidate Tumor Suppressor Gene at 3p21.3, in p53-Regulated Tumor Angiogenesis Suppression
Cancer Res., February 15, 2007; 67(4): 1451 - 1460.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
H. Li, L. Yao, T. Ouyang, J. Li, T. Wang, Z. Fan, T. Fan, B. Dong, B. Lin, J. Li, et al.
Association of p73 G4C14-to-A4T14 (GC/AT) polymorphism with breast cancer survival
Carcinogenesis, February 1, 2007; 28(2): 372 - 377.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
I. R. Watson, A. Blanch, D. C. C. Lin, M. Ohh, and M. S. Irwin
Mdm2-mediated NEDD8 Modification of TAp73 Regulates Its Transactivation Function
J. Biol. Chem., November 10, 2006; 281(45): 34096 - 34103.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
P. Lunghi, A. Costanzo, L. Salvatore, N. Noguera, L. Mazzera, A. Tabilio, F. Lo-Coco, M. Levrero, and A. Bonati
MEK1 inhibition sensitizes primary acute myelogenous leukemia to arsenic trioxide-induced apoptosis
Blood, June 1, 2006; 107(11): 4549 - 4553.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. Dominguez, J. M. Garcia, C. Pena, J. Silva, V. Garcia, L. Martinez, C. Maximiano, M. E. Gomez, J. A. Rivera, C. Garcia-Andrade, et al.
{Delta}TAp73 Upregulation Correlates With Poor Prognosis in Human Tumors: Putative In Vivo Network Involving p73 Isoforms, p53, and E2F-1
J. Clin. Oncol., February 10, 2006; 24(5): 805 - 815.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
M Guan and Y Chen
Aberrant expression of {Delta}Np73 in benign and malignant tumours of the prostate: correlation with Gleason score
J. Clin. Pathol., November 1, 2005; 58(11): 1175 - 1179.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
U. Nyman, A. Sobczak-Pluta, P. Vlachos, T. Perlmann, B. Zhivotovsky, and B. Joseph
Full-length p73{alpha} Represses Drug-induced Apoptosis in Small Cell Lung Carcinoma Cells
J. Biol. Chem., October 7, 2005; 280(40): 34159 - 34169.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
I. Dulloo and K. Sabapathy
Transactivation-dependent and -independent Regulation of p73 Stability
J. Biol. Chem., August 5, 2005; 280(31): 28203 - 28214.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
G. Liu and X. Chen
The C-terminal Sterile {alpha} Motif and the Extreme C Terminus Regulate the Transcriptional Activity of the {alpha} Isoform of p73
J. Biol. Chem., May 20, 2005; 280(20): 20111 - 20119.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
T. Hanamoto, T. Ozaki, K. Furuya, M. Hosoda, S. Hayashi, M. Nakanishi, H. Yamamoto, H. Kikuchi, S. Todo, and A. Nakagawara
Identification of Protein Kinase A Catalytic Subunit {beta} as a Novel Binding Partner of p73 and Regulation of p73 Function
J. Biol. Chem., April 29, 2005; 280(17): 16665 - 16675.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
W. H. Toh, S. Kyo, and K. Sabapathy
Relief of p53-mediated Telomerase Suppression by p73
J. Biol. Chem., April 29, 2005; 280(17): 17329 - 17338.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
R. A. Johnson, E. M. Shepard, and K. W. Scotto
Differential Regulation of MDR1 Transcription by the p53 Family Members: ROLE OF THE DNA BINDING DOMAIN
J. Biol. Chem., April 8, 2005; 280(14): 13213 - 13219.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. Flinterman, L. Guelen, S. Ezzati-Nik, R. Killick, G. Melino, K. Tominaga, J. S. Mymryk, J. Gaken, and M. Tavassoli
E1A Activates Transcription of p73 and Noxa to Induce Apoptosis
J. Biol. Chem., February 18, 2005; 280(7): 5945 - 5959.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
P. Lunghi, A. Costanzo, M. Levrero, and A. Bonati
Treatment with arsenic trioxide (ATO) and MEK1 inhibitor activates the p73-p53AIP1 apoptotic pathway in leukemia cells
Blood, July 15, 2004; 104(2): 519 - 525.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
U. M. Moll and N. Slade
p63 and p73: Roles in Development and Tumor Formation
Mol. Cancer Res., July 1, 2004; 2(7): 371 - 386.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
A Oniscu, N Sphyris, R G Morris, S Bader, and D J Harrison
p73{alpha} is a candidate effector in the p53 independent apoptosis pathway of cisplatin damaged primary murine colonocytes
J. Clin. Pathol., May 1, 2004; 57(5): 492 - 498.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
W. M. Chan, W. Y. Siu, A. Lau, and R. Y. C. Poon
How Many Mutant p53 Molecules Are Needed To Inactivate a Tetramer?
Mol. Cell. Biol., April 15, 2004; 24(8): 3536 - 3551.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
N. Concin, K. Becker, N. Slade, S. Erster, E. Mueller-Holzner, H. Ulmer, G. Daxenbichler, A. Zeimet, R. Zeillinger, C. Marth, et al.
Transdominant {Delta}TAp73 Isoforms Are Frequently Up-regulated in Ovarian Cancer. Evidence for Their Role as Epigenetic p53 Inhibitors in Vivo
Cancer Res., April 1, 2004; 64(7): 2449 - 2460.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
G. Melino, F. Bernassola, M. Ranalli, K. Yee, W. X. Zong, M. Corazzari, R. A. Knight, D. R. Green, C. Thompson, and K. H. Vousden
p73 Induces Apoptosis via PUMA Transactivation and Bax Mitochondrial Translocation
J. Biol. Chem., February 27, 2004; 279(9): 8076 - 8083.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
G. Liu, S. Nozell, H. Xiao, and X. Chen
{Delta}Np73{beta} Is Active in Transactivation and Growth Suppression
Mol. Cell. Biol., January 15, 2004; 24(2): 487 - 501.
[Abstract] [Full Text] [PDF]

Home page
 J. Cell Sci.Home page
D. Goldschneider, E. Blanc, G. Raguenez, M. Barrois, A. Legrand, G. Le Roux, H. Haddada, J. Benard, and S. Douc-Rasy
Differential response of p53 target genes to p73 overexpression in SH-SY5Y neuroblastoma cell line
J. Cell Sci., January 15, 2004; 117(2): 293 - 301.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Stiewe, S. Tuve, M. Peter, A. Tannapfel, A. H. Elmaagacli, and B. M. Putzer
Quantitative TP73 Transcript Analysis in Hepatocellular Carcinomas
Clin. Cancer Res., January 15, 2004; 10(2): 626 - 633.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
F. Frasca, V. Vella, A. Aloisi, A. Mandarino, E. Mazzon, R. Vigneri, and P. Vigneri
p73 Tumor-Suppressor Activity Is Impaired in Human Thyroid Cancer
Cancer Res., September 15, 2003; 63(18): 5829 - 5837.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
O. Petrenko, A. Zaika, and U. M. Moll
{Delta}Np73 Facilitates Cell Immortalization and Cooperates with Oncogenic Ras in Cellular Transformation In Vivo
Mol. Cell. Biol., August 15, 2003; 23(16): 5540 - 5555.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
T. Stiewe, J. Stanelle, C. C. Theseling, B. Pollmeier, M. Beitzinger, and B. M. Putzer
Inactivation of Retinoblastoma (RB) Tumor Suppressor by Oncogenic Isoforms of the p53 Family Member p73
J. Biol. Chem., April 11, 2003; 278(16): 14230 - 14236.
[Abstract] [Full Text] [PDF]

Home page
 J. Exp. Med.Home page
A. I. Zaika, N. Slade, S. H. Erster, C. Sansome, T. W. Joseph, M. Pearl, E. Chalas, and U. M. Moll
{Delta}Np73, A Dominant-Negative Inhibitor of Wild-type p53 and TAp73, Is Up-regulated in Human Tumors
J. Exp. Med., September 16, 2002; 196(6): 765 - 780.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. Stiewe, S. Zimmermann, A. Frilling, H. Esche, and B. M. Putzer
Transactivation-deficient {Delta}TA-p73 Acts as an Oncogene
Cancer Res., July 1, 2002; 62(13): 3598 - 3602.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
T. Stiewe, C. C. Theseling, and B. M. Putzer
Transactivation-deficient Delta TA-p73 Inhibits p53 by Direct Competition for DNA Binding. IMPLICATIONS FOR TUMORIGENESIS
J. Biol. Chem., April 12, 2002; 277(16): 14177 - 14185.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2002 by the American Association for Cancer Research.